Johnson & Johnson annual ebitda margin
2009
2010
2011
2012
2013
2014
2022
2023
2024
2025
Johnson & Johnson EBITDA Margin Growth & History (JNJ)
Johnson & Johnson's ebitda margin was 43.59% for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-28 | 43.59% | +15.69 pp |
| 2024 | 2024-12-29 | 27.90% | +0.52 pp |
| 2023 | 2023-12-31 | 27.38% | −5.88 pp |
| 2022 | 2023-01-01 | 33.26% | — |
| 2014 | 2014-12-28 | 34.29% | +5.52 pp |
| 2013 | 2013-12-29 | 28.77% | +1.07 pp |
| 2012 | 2012-12-30 | 27.70% | +1.68 pp |
| 2011 | 2012-01-01 | 26.02% | −7.49 pp |
| 2010 | 2011-01-02 | 33.51% | +2.24 pp |
| 2009 | 2010-01-03 | 31.27% | — |
Johnson & Johnson quarterly ebitda margin
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-28 | 35.51% | −1.31 pp |
| Q1 2026 | 2026-03-29 | 34.35% | — |
| Q4 2025 | 2025-12-28 | 29.27% | — |
| Q3 2025 | 2025-09-28 | 39.66% | — |
| Q2 2025 | 2025-06-29 | 36.82% | — |
| Q1 2015 | 2015-03-29 | 38.69% | +1.90 pp |
| Q4 2014 | 2014-12-28 | 21.92% | −0.63 pp |
| Q3 2014 | 2014-09-28 | 43.28% | +15.69 pp |
| Q2 2014 | 2014-06-29 | 35.02% | +1.40 pp |
| Q1 2014 | 2014-03-30 | 36.79% | +5.26 pp |
| Q4 2013 | 2013-12-29 | 22.56% | −2.39 pp |
| Q3 2013 | 2013-09-29 | 27.58% | −0.74 pp |
| Q2 2013 | 2013-06-30 | 33.62% | +12.32 pp |
| Q1 2013 | 2013-03-31 | 31.52% | −5.05 pp |
| Q4 2012 | 2012-12-30 | 24.94% | +14.51 pp |
| Q3 2012 | 2012-09-30 | 28.33% | −5.61 pp |
| Q2 2012 | 2012-07-01 | 21.30% | −4.70 pp |
| Q1 2012 | 2012-04-01 | 36.58% | +2.69 pp |
| Q4 2011 | 2012-01-01 | 10.43% | — |
| Q3 2011 | 2011-10-02 | 33.94% | −0.01 pp |
| Q2 2011 | 2011-07-03 | 26.00% | −7.20 pp |
| Q1 2011 | 2011-04-03 | 33.89% | — |
| Q3 2010 | 2010-10-03 | 33.95% | — |
| Q2 2010 | 2010-07-04 | 33.20% | — |
Johnson & Johnson ebitda margin trends
Between the periods ended 2010-01-03 and 2025-12-28, Johnson & Johnson's ebitda margin increased from 31.27% to 43.59%, a change of +12.31 percentage points. The latest reported quarter, Q2 2026, shows 35.51%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
